Sign In
Buy PLRX
$1.18
+0.0200 (+1.72%)
At Close: Jun 03, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
02:11pm, Thursday, 17'th Apr 2025
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such inves
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
01:45pm, Wednesday, 16'th Apr 2025
NEW YORK CITY, NY / ACCESS Newswire / April 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such investor
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims - On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
05:15pm, Tuesday, 15'th Apr 2025
NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such i
PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know
01:01pm, Thursday, 10'th Apr 2025
PLIANT THERAPT (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
04:05pm, Monday, 07'th Apr 2025
SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 Ame
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
03:08am, Saturday, 05'th Apr 2025
NEW YORK CITY, NY / ACCESS Newswire / April 5, 2025 / Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics
Pliant Therapeutics: An Activist On Deck
12:22pm, Thursday, 03'rd Apr 2025
Pliant Therapeutics suffered a major setback with its lead drug candidate, causing its stock to plummet well below its cash value. Activist investor Kevin Tang has acquired a significant stake in PLRX
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
09:59am, Friday, 28'th Mar 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options If
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know
10:40am, Thursday, 27'th Mar 2025
Pliant stock crashes 89% in three months following setbacks in the mid-stage study of its lead candidate, bexotegrast, for idiopathic pulmonary fibrosis.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX
03:19pm, Wednesday, 26'th Mar 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
08:34am, Sunday, 23'rd Mar 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
10:06am, Wednesday, 19'th Mar 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options
Antitumor activity observed with confirmed partial responses in 50% of patients at highest dose tested to date, across multiple tumor types PLN-101095 was generally well tolerated across all doses SOU
INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
10:36am, Sunday, 16'th Mar 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options NE
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
08:24am, Saturday, 15'th Mar 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options
